Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
| Autor: | Ahmed Al-Janabi, Oren Tomkins-Netzer, Amgad El Nokrashy, Lazha Sharief, Susan Lightman, Vivekka Nagendran |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Visual acuity medicine.medical_treatment Visual Acuity Biological Factors 03 medical and health sciences 0302 clinical medicine Internal medicine Panuveitis medicine Adalimumab Humans Longitudinal Studies Aged Retrospective Studies 030304 developmental biology 0303 health sciences business.industry Uveitis Posterior Immunosuppression Retrospective cohort study Middle Aged medicine.disease Infliximab Ophthalmology 030221 ophthalmology & optometry Intermediate uveitis Female medicine.symptom business Uveitis Intermediate Uveitis medicine.drug |
| Zdroj: | Ophthalmology. 127:410-416 |
| ISSN: | 0161-6420 |
| DOI: | 10.1016/j.ophtha.2019.08.031 |
| Popis: | To examine a large cohort of patients treated with biologic agents for active noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIPPU) and to compare their efficacy and long-term effect.Retrospective, longitudinal study.Eighty-two patients (156 eyes) with active NIPPU after failure of treatment with corticosteroids and a second-line immunosuppression drug and treated with biologic agents who were treated at Moorfields Eye Hospital between 2001 and 2016.Information was gathered from the clinical notes of all patients.Time to first disease flare, rate of treatment failure, best-corrected visual acuity, and risk factors for treatment failure.Patients were followed on average for 4.7±0.4 years (724 eye-years). All patients demonstrated active uveitis at baseline, and 34 patients (41.5%) demonstrated a coexisting active systemic disease. Control of ocular inflammation was achieved in 136 eyes (87.2%). The average oral prednisolone dose at baseline was 16.4±1.7 mg/day, and by 6 months reduced to 6.5±0.7 mg/day (P0.0001), remaining stable for up to 5 years follow-up. Best-corrected visual acuity at baseline was 0.5±0.1 logarithm of the minimum angle of resolution (logMAR), improved to 0.4±0.1 logMAR (P = 0.008) at 3 months, and remained stable during follow-up. After baseline, 42.3% of eyes experienced flares, and the average number of flares reduced from 1.8±0.1 flares/year to 0.6±0.1 flares/year (P0.0001). Median time to first flare was 5.4 years (95% confidence interval [CI], 2.2-5.4 years) with a 5-year survival rate of 58.7%. Treatment failed in 37 eyes (23.7%), with a 5-year survival rate of 68.0% and an estimated time to 75% survival of 2.9 years (95% CI, 2.1-4.4 years). The risk for treatment failure was lower when treatment used adalimumab (odds ratio, 0.4; 95% CI, 0.2-0.9; P = 0.03) but was greater when systemic disease also was active at baseline (odds ratio, 3.2; 95% CI, 1.5-7.1; P = 0.004).Overall, eyes treated with biologic agents after failure of treatment with corticosteroids and a second-line immunosuppression drug experienced satisfactory disease control (87.2%), reduced use of systemic immunosuppression, stable visual acuity, and a 23.7% risk of disease relapse. After multivariate adjustment, older age, treatment with adalimumab (versus infliximab), and inactive concomitant systemic disease were associated with a lower risk of treatment failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|